Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Erlotinib Hydrochloride × Lymphoid × Clear all

Phase

Phase 1 4 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 160 Gastrointestinal 69 CNS 23 Genitourinary 18 Breast 14 Tumor-Agnostic 13 Head & Neck 13 Sarcoma 12 Gynecologic 8 Other solid neoplasm 4 Other hematologic neoplasm 2 Myeloid 2 Plasma cell 1 NET 1 Lymphoid 1 Endocrine 1 Dermatologic 1

Conditions

Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1

Interventions

Rituximab 627 Cyclophosphamide 546 Vincristine 251 Etoposide 245 Doxorubicin 242 Cytarabine 203 Prednisone 201 Methotrexate 189 Filgrastim 168 Dexamethasone 163 fludarabine phosphate 161 fludarabine 157 Lenalidomide 148 Radiotherapy 118 Melphalan 112 Peripheral Blood Stem Cell Transplantation 107 Busulfan 105 Bendamustine Hydrochloride 105 Bortezomib 101 ibrutinib 100 Mycophenolic Acid 96 Granulocyte Colony-Stimulating Factor 96 venetoclax 94 Whole-Body Irradiation 92 obinutuzumab 91 Tacrolimus 86 Gemcitabine 83 zanubrutinib 75 Alemtuzumab 66 Carmustine 65

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03297606 2026-03-04

CAPTUR

Canadian Cancer Trials Group

Phase 2 Recruiting

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡